Primary progressive HD in the trials of the GHSG from 1988-1998 for intermediate and advanced stages
| Trial . | Years . | Stage . | Treatment protocol . | Total no. included . | No. of patients with PD (%) . |
|---|---|---|---|---|---|
| Intermediate stages | |||||
| HD5 | 1988-1994 | I/II + risk factors | Arm A: 2 × COPP/ABVD + EF RT | 1026 | 37 (3.6%) |
| vs | |||||
| Arm B: 2 × COPP/ABV/IMEP + EF RT | |||||
| HD8 | 1994-1998 | I/II + risk factors | Arm A: 2 × COPP/ABVD + EF RT | 1044 | 38 (3.6%) |
| vs | |||||
| Arm B: 2 × COPP/ABVD + IF RT | |||||
| Advanced stages | |||||
| HD6 | 1988-1994 | IIB + risk factors | Arm A: 4 × COPP/ABVD + RT (bulk/residual) | 600 | 82 (13.6%) |
| III/IV | vs | ||||
| Arm B: 4 × COPP/ABVD + RT (bulk/residual) | |||||
| HD9 | 1994-1998 | IIB + risk factors | Arm A: 4 × COPP/ABVD + RT (bulk/residual) | 1137 | 82 (7.2%): |
| III/IV | vs | Arm A: 13% | |||
| Arm B: 8 × BEACOPP baseline + RT (bulk/residual) | Arm B: 7% | ||||
| vs | Arm C: 2% | ||||
| Arm C: 8 × BEACOPP escalated + RT (bulk/residual) | |||||
| Trial . | Years . | Stage . | Treatment protocol . | Total no. included . | No. of patients with PD (%) . |
|---|---|---|---|---|---|
| Intermediate stages | |||||
| HD5 | 1988-1994 | I/II + risk factors | Arm A: 2 × COPP/ABVD + EF RT | 1026 | 37 (3.6%) |
| vs | |||||
| Arm B: 2 × COPP/ABV/IMEP + EF RT | |||||
| HD8 | 1994-1998 | I/II + risk factors | Arm A: 2 × COPP/ABVD + EF RT | 1044 | 38 (3.6%) |
| vs | |||||
| Arm B: 2 × COPP/ABVD + IF RT | |||||
| Advanced stages | |||||
| HD6 | 1988-1994 | IIB + risk factors | Arm A: 4 × COPP/ABVD + RT (bulk/residual) | 600 | 82 (13.6%) |
| III/IV | vs | ||||
| Arm B: 4 × COPP/ABVD + RT (bulk/residual) | |||||
| HD9 | 1994-1998 | IIB + risk factors | Arm A: 4 × COPP/ABVD + RT (bulk/residual) | 1137 | 82 (7.2%): |
| III/IV | vs | Arm A: 13% | |||
| Arm B: 8 × BEACOPP baseline + RT (bulk/residual) | Arm B: 7% | ||||
| vs | Arm C: 2% | ||||
| Arm C: 8 × BEACOPP escalated + RT (bulk/residual) | |||||
PD indicates progressive disease; RT, radiotherapy; EF, extended field; IF, involved field; COPP, cyclophosphamide, oncovin, procarbazine, prednisone; ABVD, adriamycin, bleomycin, vinblastine, darcarbazine; IMEP, ifosfamide, methotrexate, etoposide, prednisone; BEACOPP, bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, prednisone.